Please assess the completion status of the following clinical trial:

Trial Title: Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for patients with acromegaly:~* Male or female patients between 18 and 80 years~* Patients with acromegaly due to a pituitary adenoma with elevated GH and IGF-1 concentrations~Exclusion criteria for patients with acromegaly:~* Patients with compression of the optic chiasm causing any visual field defect~* Specific criteria apply for patients who have received certain types of therapies such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to study start~* Female patients who are pregnant or lactating~Inclusion criteria for patients with carcinoid disease:~* Male or female patients aged ≥18 years~* Patients with histologically confirmed, metastatic carcinoid tumors of the digestive system~* Patients with elevation of chromogranin-A (CgA) and/or serotonin~* Patients who are not adequately controlled by somatostatin analogues~Exclusion criteria for patients with carcinoid disease:~* Specific criteria apply for patients who have received certain types of therapies such as radiotherapies, surgeries, chemo- or immunotherapies in the months prior to study start~* Female patients who are pregnant or lactating~Other protocol-defined in- and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOM230 LAR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).